What is B. Riley’s Forecast for TNGX Q2 Earnings?

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities research analysts at B. Riley issued their Q2 2025 earnings estimates for Tango Therapeutics in a research report issued to clients and investors on Monday, June 9th. B. Riley analyst Y. Zhi expects that the company will earn ($0.35) per share for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.33) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The business had revenue of $5.39 million during the quarter, compared to analyst estimates of $6.73 million.

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics presently has an average rating of “Buy” and an average target price of $12.20.

Tango Therapeutics Trading Up 6.0%

TNGX opened at $4.74 on Wednesday. The business has a 50 day moving average of $1.88 and a 200-day moving average of $2.40. The stock has a market capitalization of $513.79 million, a price-to-earnings ratio of -4.02 and a beta of 1.24. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $12.02.

Institutional Trading of Tango Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC lifted its position in Tango Therapeutics by 96.6% in the first quarter. Acadian Asset Management LLC now owns 973,309 shares of the company’s stock worth $1,327,000 after purchasing an additional 478,203 shares during the period. Jane Street Group LLC raised its stake in shares of Tango Therapeutics by 270.6% in the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock valued at $483,000 after buying an additional 257,668 shares in the last quarter. Woodline Partners LP lifted its holdings in shares of Tango Therapeutics by 28.3% during the 1st quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock worth $693,000 after acquiring an additional 111,791 shares during the period. Dynamic Technology Lab Private Ltd boosted its position in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after acquiring an additional 15,037 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of Tango Therapeutics by 42.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 737,955 shares of the company’s stock valued at $1,011,000 after acquiring an additional 220,529 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.